NuVasive shares target price raised to $55 by Brean Capital: 4 quick facts

Spinal Tech

Brean Capital Equities research analysts increased their price objective on NuVasive shares from $53 to $55 in a research note, according to a Dakota Financial News report.

Here are four things to know:

 

1. Brean Capital currently has a "buy" rating on the stock.

 

2. NuVasive has a one-year low of $31.35 and a one-year high of $51.23.

 

3. The stock has a 50-day moving average of $47.23 and a 200-day moving average of $41.65.

 

4. NuVasive's market cap is $2.139 billion.

More articles on devices:

Spine device company stock report: 5 key companies — Feb. 26
Invibio Spine's PEEK-OPTIMA HA Enhanced shows promise
JMEA Corporation wins grant from Montgomery County' economic development department

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers